China-based health services and distribution giant Baheal Pharmaceutical Group (SHE: 301015) last month reached an accord with Roche (SWX: ROG, OTCMKTS: RHHBY), securing exclusive market promotion rights to the Swiss giant’s MabThera (rituximab) in mainland China.
Drug Profile
MabThera, the world’s first anti-CD20 monoclonal antibody (mAb), is used to treat Hodgkin lymphoma and chronic lymphocytic leukemia, among other conditions. First approved in China in April 2000, the drug entered the National Reimbursement Drug List (NRDL) in July 2017. It went on to receive two new major indication approvals in China in 2019.-Fineline Info & Tech
Leave a Reply